ATOS had 90% of Forecyte in their warehouse plus only sold 500k worth of inventory. Costs associated won't be much...also only have address these concerns before it can be remarketed.
The FDA raised concerns about (1) the current instructions for use (IFU); (2) certain promotional claims used to market these devices; and (3) the need for FDA clearance for certain changes made to the Nipple Aspirate Fluid (NAF) specimen collection process identified in the current IFU. Atossa will remove existing product from the market until FDA’s concerns are addressed.
Not to mention they have an excellent pipeline and enough capital to keep them running for 8-12 months. Could have massive upside. Steal at only a 30M valuation